Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05349097 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate IMG-004 in Healthy Participants
A Phase 1 study, sponsored by Inmagene.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT05349097: Completed Phase 1 study, sponsored by Inmagene.
NCT05349097 is a Phase 1 study that has completed, run by Inmagene. The registered enrollment target is 72 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05349097, a Phase 1 study, has completed, sponsored by Inmagene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
A Phase 1, Randomized, Double-blind, Placebo-controlled Study of Orally Administered IMG-004 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Dose(s) and an Open-Label Study of Single Oral Dose of IMG-004 to Evaluate the Food Effect in Healthy Participants
Primary Outcome
Incidence and severity of AEs, including clinically relevant findings from vital signs, physical examination, laboratory tests, and 12-lead ECG
Interventions
- DRUG SAD IMG-004 30mg
- DRUG SAD IMG-004 100mg
- DRUG SAD IMG-004 200mg
- DRUG SAD IMG-004 400mg
- DRUG SAD IMG-004 600mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2022-08-08 |
| Est. Completion | 2024-05-02 |
| Phase | Phase 1 |
What the finished NCT05349097 record still lists
NCT05349097 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher).
The record links to 0 conditions, and to 5 interventions - of which SAD IMG-004 30mg is the first listed.
NCT05349097 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05349097 about?
NCT05349097 is a clinical study titled "Study to Evaluate IMG-004 in Healthy Participants". A Phase 1, Randomized, Double-blind, Placebo-controlled Study of Orally Administered IMG-004 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Dose(s) and an Open-Label Study of Single Oral Dose of IMG-004 to Evaluate the Food Effect in Healthy Participants
What is the current status of trial NCT05349097?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2022-08-08. Estimated completion is 2024-05-02.
What interventions are being tested in trial NCT05349097?
The interventions under investigation include: SAD IMG-004 30mg (DRUG), SAD IMG-004 100mg (DRUG), SAD IMG-004 200mg (DRUG), SAD IMG-004 400mg (DRUG), SAD IMG-004 600mg (DRUG).
Who is sponsoring clinical trial NCT05349097?
This trial is sponsored by Inmagene, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05349097's enrollment target sits among peer trials
72 736th of 2000 higher than 1,254 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI